Item Type | Name |
Concept
|
Breast Neoplasms
|
Academic Article
|
Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
|
Academic Article
|
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
|
Academic Article
|
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.
|
Academic Article
|
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.
|
Academic Article
|
Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells.
|
Academic Article
|
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
|
Academic Article
|
Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer.
|
Academic Article
|
A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
|
Academic Article
|
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.
|
Concept
|
Triple Negative Breast Neoplasms
|
Academic Article
|
PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer.
|
Academic Article
|
c-erbB-2 in breast cancer: development of a clinically useful marker.
|
Academic Article
|
Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy.
|
Academic Article
|
An academic health center cost analysis of screening mammography: creating a financially viable service.
|
Academic Article
|
Sentinel node biopsy prior to neoadjuvant chemotherapy.
|
Academic Article
|
Detection and Significance of Occult Axillary Metastatic Disease in Breast Cancer Patients.
|
Academic Article
|
Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869.
|
Academic Article
|
Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients.
|
Academic Article
|
New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK.
|
Academic Article
|
Invasive breast cancer.
|
Academic Article
|
A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
|
Academic Article
|
Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme.
|
Academic Article
|
Approach to menopausal symptoms in women with breast cancer.
|
Academic Article
|
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.
|
Academic Article
|
Prognostic and predictive factors for breast cancer: translating technology to oncology.
|
Academic Article
|
A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia.
|
Academic Article
|
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
|
Academic Article
|
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
|
Academic Article
|
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual.
|
Academic Article
|
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
|
Academic Article
|
HER2 and response to paclitaxel in node-positive breast cancer.
|
Academic Article
|
Heart of darkness: the downside of trastuzumab.
|
Academic Article
|
Protocol for the examination of specimens from patients with invasive carcinoma of the breast.
|
Academic Article
|
Is there a role for circulating tumor cells in the management of breast cancer?
|
Academic Article
|
Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy?
|
Academic Article
|
Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants.
|
Academic Article
|
Breast cancer. Clinical practice guidelines in oncology.
|
Academic Article
|
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897.
|
Academic Article
|
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).
|
Academic Article
|
Editorial: Cost-effective analyses in Breast Cancer Research and Treatment [corrected].
|
Academic Article
|
Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.
|
Academic Article
|
Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer.
|
Academic Article
|
Invasive breast cancer.
|
Academic Article
|
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
|
Academic Article
|
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
|
Academic Article
|
Adjuvant systemic therapy for elderly women with breast cancer.
|
Academic Article
|
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.
|
Academic Article
|
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
|
Academic Article
|
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
|
Academic Article
|
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.
|
Academic Article
|
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.
|
Academic Article
|
Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets.
|
Academic Article
|
A Diet and Exercise Intervention during Chemotherapy for Breast Cancer.
|
Academic Article
|
Indications for prognostic gene expression profiling in early breast cancer.
|
Academic Article
|
Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast.
|
Academic Article
|
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
|
Academic Article
|
From genome to bedside: are we lost in translation?
|
Academic Article
|
Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast.
|
Academic Article
|
CYP2D6 testing for breast cancer patients: is there more to the story?
|
Academic Article
|
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
|
Academic Article
|
Pretreatment worry and neurocognitive responses in women with breast cancer.
|
Academic Article
|
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
|
Academic Article
|
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary.
|
Academic Article
|
An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer.
|
Academic Article
|
Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.
|
Academic Article
|
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.
|
Academic Article
|
A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.
|
Academic Article
|
Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration.
|
Academic Article
|
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.
|
Academic Article
|
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
|
Academic Article
|
Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.
|
Academic Article
|
Markers of increased risk for failure of adjuvant therapies.
|
Academic Article
|
Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy.
|
Academic Article
|
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
|
Academic Article
|
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
|
Academic Article
|
Breast cancer.
|
Academic Article
|
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
|
Academic Article
|
Combination anastrozole and fulvestrant in metastatic breast cancer.
|
Academic Article
|
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.
|
Academic Article
|
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
|
Academic Article
|
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
|
Academic Article
|
Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
|
Academic Article
|
A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222.
|
Academic Article
|
Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer.
|
Academic Article
|
Monitoring serial changes in circulating human breast cancer cells in murine xenograft models.
|
Academic Article
|
Molecular testing in breast cancer.
|
Academic Article
|
Pharmacogenomics and Endocrine Therapy in Breast Cancer.
|
Academic Article
|
Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence.
|
Academic Article
|
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer.
|
Academic Article
|
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
|
Academic Article
|
Prediction of postchemotherapy ovarian function using markers of ovarian reserve.
|
Academic Article
|
Correction to: Targeted degradation of activating estrogen receptor a ligand-binding domain mutations in human breast cancer.
|
Academic Article
|
Breast cancer: noninvasive and special situations.
|
Academic Article
|
Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.
|
Academic Article
|
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
|
Academic Article
|
Tamoxifen therapy for patients with breast cancer.
|
Academic Article
|
Breast cancer version 3.2014.
|
Academic Article
|
Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy.
|
Academic Article
|
Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer.
|
Academic Article
|
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
|
Academic Article
|
Muscle mass affects paclitaxel systemic exposure and may inform personalized paclitaxel dosing.
|
Academic Article
|
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
|
Academic Article
|
International Web-based consultation on priorities for translational breast cancer research.
|
Academic Article
|
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
|
Academic Article
|
Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.
|
Academic Article
|
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
|
Academic Article
|
Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
|
Academic Article
|
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.
|
Academic Article
|
Clinical practice. Follow-up of patients with early breast cancer.
|
Academic Article
|
Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
|
Academic Article
|
The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.
|
Academic Article
|
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
|
Academic Article
|
Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
|
Academic Article
|
p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy.
|
Academic Article
|
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.
|
Academic Article
|
Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breast cancer?
|
Academic Article
|
Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models.
|
Academic Article
|
Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.
|
Academic Article
|
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
|
Academic Article
|
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
|
Academic Article
|
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
|
Academic Article
|
Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.
|
Academic Article
|
Development and validation of sandwich ELISA microarrays with minimal assay interference.
|
Academic Article
|
Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer.
|
Academic Article
|
Is Breast Cancer a Curable Disease?
|
Academic Article
|
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.
|
Academic Article
|
Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms.
|
Academic Article
|
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
|
Academic Article
|
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.
|
Academic Article
|
Reply to G. Sauter et al.
|
Academic Article
|
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
|
Academic Article
|
ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.
|
Academic Article
|
Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.
|
Academic Article
|
Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.
|
Academic Article
|
Tamoxifen: Dr. Jekyll and Mr. Hyde?
|
Academic Article
|
An international study to increase concordance in Ki67 scoring.
|
Academic Article
|
Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
|
Academic Article
|
AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist.
|
Academic Article
|
Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.
|
Academic Article
|
Defining the benefits of neoadjuvant chemotherapy for breast cancer.
|
Academic Article
|
Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.
|
Academic Article
|
Reply to R. Bhargava et al and K. Lambein et al.
|
Academic Article
|
Thymidine kinase activity levels in serum can identify HR+?metastatic breast?cancer patients with a low risk of early progression (SWOG S0226).
|
Academic Article
|
Markers of endocrine sensitivity.
|
Academic Article
|
Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?
|
Academic Article
|
Disease related indicators for a proper choice of adjuvant treatments.
|
Academic Article
|
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.
|
Academic Article
|
Reply to E.A. Rakha et al.
|
Academic Article
|
CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer.
|
Academic Article
|
Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.
|
Academic Article
|
Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer.
|
Academic Article
|
Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility.
|
Academic Article
|
Promoting quality and evidence-based care in early-stage breast cancer follow-up.
|
Academic Article
|
Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.
|
Academic Article
|
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
|
Academic Article
|
Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer.
|
Academic Article
|
Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation.
|
Academic Article
|
Breast-Cancer Recurrence after Stopping Endocrine Therapy.
|
Academic Article
|
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.
|
Academic Article
|
Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.
|
Academic Article
|
Factors influencing the use of extended adjuvant endocrine therapy.
|
Academic Article
|
Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.
|
Academic Article
|
Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy.
|
Academic Article
|
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.
|
Academic Article
|
Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: an old(er) problem.
|
Academic Article
|
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.
|
Academic Article
|
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
|
Academic Article
|
HER2 and Breast Cancer - A Phenomenal Success Story.
|
Academic Article
|
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
|
Academic Article
|
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models.
|
Academic Article
|
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
|
Academic Article
|
Tamoxifen-induced radiation recall dermatitis.
|
Academic Article
|
Prechemotherapy alterations in brain function in women with breast cancer.
|
Academic Article
|
Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial.
|
Academic Article
|
Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation.
|
Academic Article
|
CYP2D6 genotype and tamoxifen response.
|
Academic Article
|
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
|
Academic Article
|
Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer.
|
Academic Article
|
The prognostic implications of circulating tumor cells in patients with breast cancer.
|
Academic Article
|
Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.
|
Academic Article
|
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.
|
Academic Article
|
Recent translational research: circulating tumor cells in breast cancer patients.
|
Academic Article
|
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
|
Academic Article
|
Revision of the American Joint Committee on Cancer staging system for breast cancer.
|
Academic Article
|
Angiogenesis as targeted breast cancer therapy.
|
Academic Article
|
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.
|
Academic Article
|
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
|
Academic Article
|
Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer.
|
Academic Article
|
A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.
|
Academic Article
|
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221).
|
Academic Article
|
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.
|
Academic Article
|
Do all patients with breast cancer require systemic adjuvant therapy?
|
Academic Article
|
Reply to F.-C. Bidard et al.
|
Academic Article
|
Contribution of biomarkers to personalized medicine.
|
Academic Article
|
Breast cancer, version 3.2013: featured updates to the NCCN guidelines.
|
Academic Article
|
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
|
Academic Article
|
Gene expression profiling of breast cancer: a new tumor marker.
|
Academic Article
|
Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial.
|
Academic Article
|
Playing the old piano: another tune for endocrine therapy?
|
Academic Article
|
An international Ki67 reproducibility study.
|
Academic Article
|
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
|
Academic Article
|
ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.
|
Academic Article
|
Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.
|
Academic Article
|
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
|
Academic Article
|
Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622.
|
Academic Article
|
Cognitive dysfunction and symptom burden in women treated for breast cancer: a prospective behavioral and fMRI analysis.
|
Academic Article
|
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients.
|
Academic Article
|
Circulating Tumor Cells.
|
Academic Article
|
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
|
Academic Article
|
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.
|
Academic Article
|
Surveillance and monitoring in breast cancer survivors: maximizing benefit and minimizing harm.
|
Academic Article
|
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
|
Academic Article
|
Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.
|
Academic Article
|
Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer.
|
Academic Article
|
Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses.
|
Academic Article
|
Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation.
|
Academic Article
|
Cyclin E as a prognostic factor: what is the question?
|
Academic Article
|
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
|
Academic Article
|
Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator.
|
Academic Article
|
Clinical Applications of Circulating Tumor Cells in Breast Cancer.
|
Academic Article
|
Assessing the measure of a new drug: is survival the only thing that matters?
|
Academic Article
|
Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer.
|
Academic Article
|
Further Progress for Patients with Breast Cancer.
|
Academic Article
|
Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy.
|
Academic Article
|
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer.
|
Academic Article
|
Progress in the Treatment of Breast Cancer. Reply.
|
Academic Article
|
Neoadjuvant Chemotherapy: What Are the Benefits for the Patient and for the Investigator?
|
Academic Article
|
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.
|
Academic Article
|
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.
|
Academic Article
|
Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
|
Academic Article
|
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.
|
Academic Article
|
Targeting adjuvant chemotherapy: a good idea that needs to be proven!
|
Academic Article
|
Targeted degradation of activating estrogen receptor a ligand-binding domain mutations in human breast cancer.
|
Academic Article
|
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
|
Academic Article
|
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.
|
Academic Article
|
Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial.
|
Academic Article
|
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial.
|
Academic Article
|
Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity.
|
Academic Article
|
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
|
Academic Article
|
A multicenter randomized clinical trial evaluating interleukin-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high risk breast cancer patients.
|
Academic Article
|
A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
|
Academic Article
|
p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).
|
Academic Article
|
Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study.
|
Academic Article
|
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
|
Academic Article
|
Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer.
|
Academic Article
|
Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment.
|
Academic Article
|
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.
|
Academic Article
|
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology-College of American Pathologists Guideline Update.
|
Academic Article
|
Breast Cancer Circulating Tumor Cells: Current Clinical Applications and Future Prospects.
|
Academic Article
|
Polypharmacy, over-the-counter medications, and aromatase inhibitor adherence in early-stage breast cancer.
|
Academic Article
|
Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.
|
Academic Article
|
Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial.
|